Compare Heron Therapeutics Inc (HRTX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Prospect Capital Corporation — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: Prospect Capital Corporation is far larger — about 13.3× Heron Therapeutics Inc's market cap, and Prospect Capital Corporation pays a 22.76% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Prospect Capital Corporation for 78 Days on average.
| HRTX | PSEC | |
|---|---|---|
Market Cap | $74.04M | $984.89M |
Volume | 3,668,095 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $1.49 | $3.05 |
52-Week Low | $0.27 | $1.82 |
Typical Hold Time | 35 Days | 78 Days |
Enterprise Value | $180.78M | $2.74B |
Dividend Yield | — | 22.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
PSEC trades at $1.82, down 0.55% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has beaten EPS estimates for the last three quarters, though revenue and net income were negative in 2025. Recent news highlights dividend declarations and management commentary on market opportunities, but financial performance shows volatility with a sharp revenue decline in 2025.
The outlook is mixed; a low P/B ratio of 0.34 suggests potential undervaluation, but negative cash flow and inconsistent profitability pose risks. Analyst sentiment is cautious with a majority Hold rating. Key opportunities include dividend yield and earnings beats, while risks involve financial instability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
